开云app官网登录入口网页版-官方正版

#Takayasu动脉炎#

8篇内容 | 1321人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2124702, encodeId=13252124e0284, content=<a href='/topic/show?id=cc221e1033d' target=_blank style='color:#2F92EE;'>#Takayasu动脉炎#</a>（TA）是一种罕见于儿童和婴儿的<a href='/topic/show?id=da4c4399516' target=_blank style='color:#2F92EE;'>#大血管血管炎#</a>。<a href='/topic/show?id=8eeb8e122c6' target=_blank style='color:#2F92EE;'>#英夫利昔单抗#</a>的完全缓解率最高（40%）。促使完全缓解的其他药物是<a href='/topic/show?id=73216852458' target=_blank style='color:#2F92EE;'>#环磷酰胺#</a>（40%）和<a href='/topic/show?id=674769813be' target=_blank style='color:#2F92EE;'>#甲氨蝶呤#</a>（38%）。58%的患者需要进行侵入性手术。最常见的并发症是<a href='/topic/show?id=e33a51591f8' target=_blank style='color:#2F92EE;'>#心脏病#</a>（50%）、<a href='/topic/show?id=b64035999ca' target=_blank style='color:#2F92EE;'>#卒中#</a>（42%）和严重感染（33%）。没有患者死亡。, objectTitle=Rheumatology：婴儿Takayasu，临床特征和长期结果, objectType=article, longId=751521, objectId=17b5e5152162, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221211/1670739228160_5610093.png, objectUrl=/article/show_article.do?id=17b5e5152162, replyNumber=0, likeNumber=134, createdTime=2023-04-10, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=17b5e5152162, moduleTitle=Rheumatology：婴儿Takayasu，临床特征和长期结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=17b5e5152162)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2109296, encodeId=a3c22109296cd, content=<a href='/topic/show?id=cc221e1033d' target=_blank style='color:#2F92EE;'>#Takayasu动脉炎#</a>Takayasu动脉炎 (TAK) 又称高安血管炎、无脉症、特发性主动脉炎，是一种罕见的肉芽肿性大血管炎，侵犯主动脉及其主要分支和肺动脉。TAK可导致梗阻性和动脉瘤性血管病变，是本病发病和死亡的主要原因。经皮介入治疗TAK血管病变的现状仍未得到解决。该研究旨在探索适合TAK的经皮介入治疗策略。, objectTitle=Takayasu动脉炎, objectType=topic, longId=17103, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=79, createdTime=2023-01-07, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1972306, encodeId=d90519e230694, content=<a href='/topic/show?id=cc221e1033d' target=_blank style='color:#2F92EE;'>#Takayasu动脉炎#</a>, objectTitle=ARD：Takayasu动脉炎中托法替尼对比甲氨蝶呤的治疗效果和安全性：一项前瞻性研究观察性研究, objectType=article, longId=294676, objectId=17652946e63b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17652946e63b, replyNumber=0, likeNumber=103, createdTime=2022-02-08, rootId=0, userName=gujh, userId=3333505, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17652946e63b, moduleTitle=ARD：Takayasu动脉炎中托法替尼对比甲氨蝶呤的治疗效果和安全性：一项前瞻性研究观察性研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=17652946e63b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1972304, encodeId=3d7219e2304a5, content=<a href='/topic/show?id=cc221e1033d' target=_blank style='color:#2F92EE;'>#Takayasu动脉炎#</a>, objectTitle=Eur Heart J：Takayasu动脉炎相关肺动脉高压的临床特征和生存率, objectType=article, longId=216965, objectId=0e322169655d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e322169655d, replyNumber=0, likeNumber=87, createdTime=2022-02-13, rootId=0, userName=gujh, userId=3333505, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e322169655d, moduleTitle=Eur Heart J：Takayasu动脉炎相关肺动脉高压的临床特征和生存率, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0e322169655d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1972307, encodeId=8a3e19e2307f5, content=<a href='/topic/show?id=cc221e1033d' target=_blank style='color:#2F92EE;'>#Takayasu动脉炎#</a>, objectTitle=Stroke：Takayasu动脉炎患者的脑血管缺血事件, objectType=article, longId=302131, objectId=56db3021319d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56db3021319d, replyNumber=0, likeNumber=92, createdTime=2022-06-14, rootId=0, userName=gujh, userId=3333505, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56db3021319d, moduleTitle=Stroke：Takayasu动脉炎患者的脑血管缺血事件, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=56db3021319d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1972305, encodeId=594319e2305b5, content=<a href='/topic/show?id=cc221e1033d' target=_blank style='color:#2F92EE;'>#Takayasu动脉炎#</a>, objectTitle=Takayasu动脉炎肺动脉受累的临床特征, objectType=article, longId=221527, objectId=480a22152e9b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=480a22152e9b, replyNumber=0, likeNumber=104, createdTime=2022-11-01, rootId=0, userName=gujh, userId=3333505, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=480a22152e9b, moduleTitle=Takayasu动脉炎肺动脉受累的临床特征, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=480a22152e9b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1972303, encodeId=050a19e230374, content=<a href='/topic/show?id=cc221e1033d' target=_blank style='color:#2F92EE;'>#Takayasu动脉炎#</a>, objectTitle=NEJM：Takayasu动脉炎的视网膜血管炎-病例报道, objectType=article, longId=139010, objectId=375613901037, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=375613901037, replyNumber=0, likeNumber=109, createdTime=2018-06-11, rootId=0, userName=gujh, userId=3333505, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=375613901037, moduleTitle=NEJM：Takayasu动脉炎的视网膜血管炎-病例报道, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=375613901037)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1972302, encodeId=d41219e23025a, content=<a href='/topic/show?id=cc221e1033d' target=_blank style='color:#2F92EE;'>#Takayasu动脉炎#</a>, objectTitle=Arthritis Rheumatol：阿巴西普（CTLA-4Ig）治疗Takayasu动脉炎的随机双盲试验, objectType=article, longId=95068, objectId=8fa695068f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fa695068f2, replyNumber=0, likeNumber=102, createdTime=2018-03-06, rootId=0, userName=gujh, userId=3333505, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fa695068f2, moduleTitle=Arthritis Rheumatol：阿巴西普（CTLA-4Ig）治疗Takayasu动脉炎的随机双盲试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8fa695068f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

Takayasu动脉炎

2020-05-29

侠胆医心 (审核中...)

前往app查看评论内容

全文收起 #Takayasu动脉炎#（TA）是一种罕见于儿童和婴儿的#大血管血管炎#。#英夫利昔单抗#的完全缓解率最高（40%）。促使完全缓解的其他药物是#环磷酰胺#（40%）和#甲氨蝶呤#（38%）。58%的患者需要进行侵入性手术。最常见的并发症是#心脏病#（50%）、#卒中#（42%）和严重感染（33%）。没有患者死亡。

Rheumatology：婴儿Takayasu，临床特征和长期结果

2023-04-10发表于上海

yangchou (审核中...)

前往app查看评论内容

全文收起 #Takayasu动脉炎#Takayasu动脉炎 (TAK) 又称高安血管炎、无脉症、特发性主动脉炎，是一种罕见的肉芽肿性大血管炎，侵犯主动脉及其主要分支和肺动脉。TAK可导致梗阻性和动脉瘤性血管病变，是本病发病和死亡的主要原因。经皮介入治疗TAK血管病变的现状仍未得到解决。该研究旨在探索适合TAK的经皮介入治疗策略。

2023-01-07

gujh (审核中...)

前往app查看评论内容

#Takayasu动脉炎#

ARD：Takayasu动脉炎中托法替尼对比甲氨蝶呤的治疗效果和安全性：一项前瞻性研究观察性研究

2022-02-08

gujh (审核中...)

前往app查看评论内容

#Takayasu动脉炎#

Eur Heart J：Takayasu动脉炎相关肺动脉高压的临床特征和生存率

2022-02-13

gujh (审核中...)

前往app查看评论内容

#Takayasu动脉炎#

Stroke：Takayasu动脉炎患者的脑血管缺血事件

2022-06-14

gujh (审核中...)

前往app查看评论内容

#Takayasu动脉炎#

Takayasu动脉炎肺动脉受累的临床特征

2022-11-01

gujh (审核中...)

前往app查看评论内容

#Takayasu动脉炎#

NEJM：Takayasu动脉炎的视网膜血管炎-病例报道

2018-06-11

gujh (审核中...)

前往app查看评论内容

#Takayasu动脉炎#

Arthritis Rheumatol：阿巴西普（CTLA-4Ig）治疗Takayasu动脉炎的随机双盲试验

2018-03-06

科室
- - 订阅+
  - 更多科室
工具
服务